<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DDI-DrugBank.d31">
    <sentence id="DDI-DrugBank.d31.s0" text="MAO inhibitors should be used with caution in patients receiving hydralazine.">
        <entity charOffset="0-13" id="DDI-DrugBank.d31.s0.e0" text="MAO inhibitors" type="group"/>
        <entity charOffset="65-75" id="DDI-DrugBank.d31.s0.e1" text="hydralazine" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d31.s0.e0" e2="DDI-DrugBank.d31.s0.e1" id="DDI-DrugBank.d31.s0.p0" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s1" text="When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.">
        <entity charOffset="27-48" id="DDI-DrugBank.d31.s1.e0" text="antihypertensive drugs" type="group"/>
        <entity charOffset="59-67" id="DDI-DrugBank.d31.s1.e1" text="diazoxide" type="drug"/>
        <entity charOffset="99-109" id="DDI-DrugBank.d31.s1.e2" text="hydralazine" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d31.s1.e0" e2="DDI-DrugBank.d31.s1.e1" id="DDI-DrugBank.d31.s1.p0" type="effect"/>
        <pair ddi="true" e1="DDI-DrugBank.d31.s1.e0" e2="DDI-DrugBank.d31.s1.e2" id="DDI-DrugBank.d31.s1.p1" type="effect"/>
        <pair ddi="false" e1="DDI-DrugBank.d31.s1.e1" e2="DDI-DrugBank.d31.s1.e2" id="DDI-DrugBank.d31.s1.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s2" text="Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.">
        <entity charOffset="45-53" id="DDI-DrugBank.d31.s2.e0" text="diazoxide" type="drug"/>
        <entity charOffset="69-79" id="DDI-DrugBank.d31.s2.e1" text="hydralazine" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d31.s2.e0" e2="DDI-DrugBank.d31.s2.e1" id="DDI-DrugBank.d31.s2.p0" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s3" text="Beta-blockers (metoprolol, propranolol) serum concentrations and pharmacologic effects may be increased.">
        <entity charOffset="0-12" id="DDI-DrugBank.d31.s3.e0" text="Beta-blockers" type="group"/>
        <entity charOffset="15-24" id="DDI-DrugBank.d31.s3.e1" text="metoprolol" type="drug"/>
        <entity charOffset="27-37" id="DDI-DrugBank.d31.s3.e2" text="propranolol" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d31.s3.e0" e2="DDI-DrugBank.d31.s3.e1" id="DDI-DrugBank.d31.s3.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d31.s3.e0" e2="DDI-DrugBank.d31.s3.e2" id="DDI-DrugBank.d31.s3.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d31.s3.e1" e2="DDI-DrugBank.d31.s3.e2" id="DDI-DrugBank.d31.s3.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s4" text="Monitor cardiovascular status."/>
    <sentence id="DDI-DrugBank.d31.s5" text="Propranolol increases hydralazines serum concentrations.">
        <entity charOffset="0-10" id="DDI-DrugBank.d31.s5.e0" text="Propranolol" type="drug"/>
        <entity charOffset="22-32" id="DDI-DrugBank.d31.s5.e1" text="hydralazine" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d31.s5.e0" e2="DDI-DrugBank.d31.s5.e1" id="DDI-DrugBank.d31.s5.p0" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s6" text="Acebutolol, atenolol, and nadolol (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.">
        <entity charOffset="0-9" id="DDI-DrugBank.d31.s6.e0" text="Acebutolol" type="drug"/>
        <entity charOffset="12-19" id="DDI-DrugBank.d31.s6.e1" text="atenolol" type="drug"/>
        <entity charOffset="26-32" id="DDI-DrugBank.d31.s6.e2" text="nadolol" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d31.s6.e0" e2="DDI-DrugBank.d31.s6.e1" id="DDI-DrugBank.d31.s6.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d31.s6.e0" e2="DDI-DrugBank.d31.s6.e2" id="DDI-DrugBank.d31.s6.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d31.s6.e1" e2="DDI-DrugBank.d31.s6.e2" id="DDI-DrugBank.d31.s6.p2"/>
    <negationtags>Acebutolol, atenolol, and nadolol (low hepatic clearance or &lt;scope&gt; &lt;cue&gt; no &lt;/cue&gt; first-pass metabolism) are unlikely to be affected. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d31.s7" text="NSAIDs may decrease the hemodynamic effects of hydralazine;">
        <entity charOffset="0-5" id="DDI-DrugBank.d31.s7.e0" text="NSAIDs" type="group"/>
        <entity charOffset="47-57" id="DDI-DrugBank.d31.s7.e1" text="hydralazine" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d31.s7.e0" e2="DDI-DrugBank.d31.s7.e1" id="DDI-DrugBank.d31.s7.p0" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s8" text="avoid use if possible or closely monitor cardiovascular status at the end of drug interactions"/>
</document>